Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.36 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.36 |
| ▸ | PLOD1 | Q02809 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 3/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14984306 | 0.82 | PRKCQ (0.46) | GRM4ADORA2ACNR2CNR1FLT3 | |
| SCHEMBL8967603 | 0.80 | ADORA2A (0.41) | ADORA2AADORA1PLOD2PLOD3PLOD1 | |
| SCHEMBL8967508 | 0.79 | CYP11B1 (0.47) | ADORA2AADORA1PLOD2PLOD3PLOD1 | |
| SCHEMBL8967846 | 0.72 | ADORA2A (0.40) | ADORA2AADORA1PLOD2PLOD3PLOD1 | |
| SCHEMBL5378862 | 0.69 | CTNNB1 (0.52) | GAAPLOD2PLOD3PLOD1ALDH1A1 | |
| SCHEMBL8967897 | 0.69 | PRKCQ (0.41) | ADORA2AADORA1PLOD2PLOD3PLOD1 | |
| SCHEMBL9012778 | 0.67 | PRKCQ (0.46) | GRM4CNR2FLT3 | |
| SCHEMBL8967851 | 0.65 | PRKCQ (0.55) | ADORA2AADORA1PLOD2PLOD3PLOD1 | |
| SCHEMBL8967883 | 0.65 | PRKCQ (0.49) | ADORA2AADORA1ALDH1A1FLT3 | |
| SCHEMBL27603597 | 0.64 | L3MBTL1 (0.61) | GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221334-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | US | disclosed |
| US-8188071-B2 | Amino substituted pyridines as potent kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221334-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | GRM4 3721/4885PADI4 2471/4885ADORA2A 2571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.